DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/t2sxhm/the_us_specialty) has announced the addition of the "The US Specialty Pharmaceutical Market Report: 2012 Edition" report to their offering.
The specialty drugs cater to the disease areas like deep vein thrombosis, cancer, multiple sclerosis, HIV, hepatitis C, cardiovascular and autoimmune diseases among others. These diseases are quite difficult to treat and require special drugs for placating the condition. The respective therapeutic molecules and biologics require special packaging, handling and distribution channel termed as specialty distribution when taken together, and are sold via specialty pharmacies.
The specialty pharma realm is intensely competitive with numerous corporations holding the reins of the same.
This report provides a comprehensive overview of the US specialty pharmaceutical market covering various disease segments and the specialty pharmacy market.
The leading industry players featured include Pfizer, Amgen, Roche, Eli Lilly, NovoNordisk and J&J.
Also, market dynamics viz., key trends, industry developments, growth drivers and the challenges faced by the industry are discussed in detail.
Key Topics Covered
1. Specialty Pharmaceuticals
1.1.1 Specialty Pharmaceuticals Vs Traditional Drugs
1.2 Key Application Areas of Specialty Pharmaceuticals
1.3 Specialty Products Distribution
1.4 Specialty Pharmacy
1.4.1 Services Provided by Specialty Pharmacy
1.4.2 Value Proposition of Specialty Pharmacy
1.5 Specialty Distribution
1.5.1 Specialty Distribution Services
2. Specialty Pharmaceutical Market Size
2.1 The US Specialty Pharmaceutical Market
3. Market Dynamics
3.1 Key Trends
3.1.1 Increasing M&A activities
3.1.2 Advent of Biosimilars and Biobetters
3.2 Industry Developments
3.2.1 Ongoing Clinical Trials and Novel Product Development
3.2.2 Projected Novel Therapeutic Product Launches
3.2.3 Improved Biological Molecule Formulations
3.3 Growth Drivers
3.3.1 Higher Spending on Medicines
3.3.2 Upcoming Patent Expiries of Original Bio Drugs
3.3.3 Quick Acceptance of Biologics Worldwide
3.3.4 Launch of NMEs (New Molecular Entities)
3.3.5 Growth in Therapeutic Drug Markets and Increasing Patient Population
3.3.6 Rising Demand for Better Healthcare Options
3.3.7 Growing Ageing Population
3.3.8 Rising Healthcare Expenditure
3.4.1 Sluggish Pace of Innovation
3.4.2 Requirement of Extensive Clinical Trials for Obtaining Approval
3.4.3 Abusive Uses of Therapeutic Drugs
3.4.4 Escalating Price Pressure
4. Competitive Landscape
5. Company Profiles
6. Market Outlook
For more information, including full table of contents, please visit http://www.researchandmarkets.com/research/t2sxhm/the_us_specialty